conforming to the description of the protein deficient pancreatic diabetes type in Ethiopian patients were compared with Type i (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic. Fourteen of 39 malnutriton-related diabetes mellitus patients had fat malabsorption compared with only two of ten Type i diabetic patients and one of nine control subjects. Xylose absorption was normal favouring a pancreatic cause for the malabsorption. Plasma C-peptide during oral glucose tolerance test was significantly lower than that in Type 2 diabetic patients and normal control subjects (p < 0.01 to 0.001) and was also consistently but not significantly higher than in Type 1 diabetic patients. Glucagon secretion patterns were similar in malnutriton-related and Type 1 diabetic patients. Of 23 new malnutrition-related diabetic patients treated with glibenclamide after nutritional rehabilitation and insulin treatment, only three responded, 14 were unresponsive but remained ketosis free for over eight days while another six developed ketoacidosis or significant ketonuria within two to six days during the trial. Sixteen unselected Type 1 diabetic patients who discontinued their insulin therapy all developed frank ketoacidosis after a mean of 5.5 days. The similarity of the malnutrition-related and Type i diabetes mellitus in age of onset, insulin requirement for diabetic control and appearance of ketosis-proneness in some cases, together with the similarity of C-peptide and glucagon secretion patterns suggest that the protein deficient pancreatic diabetes variant of malnutrition-related diabetes mellitus may be Type i diabetes mellitus modified by the background of malnutrition rather than an aetiologically separate entity. Community based studies are required to ascertain frequency and types of diabetes mellitus in malnourished populations and the role of genetics and environment in their aetiology.
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A preliminary study of diabetes mellitus associated with malnutrition in Ethiopian patients [1] had shown that the majority were young adults from a poor socioeconomic background susbsisting on a diet inadequate in animal protein and vitamins (ascorbic acid in particular) and persistently or seasonally in food energy as well [2, 3] . Patients presented with classic symptoms of thirst, polyuria and wasting often of several months' or a few years' duration but had little or no ketoacidosis. Attempts to control their hyperglycaemia with oral agents, on admission to hospital or after initial treatment with insulin therapy, were unsuccessful in the majority of cases. However, these patients did not develop ketoacidosis after withdrawal of insulin therapy. They thus demonstrated the need for insulin and ketosis-resistance, well-known characteristics of malnutrition-related diabetes mellitus (MRDM). Of the two main variants of MRDM, i. e. the fibrocalcific pancreatic diabetes (FCPD) and the protein deficient pancreatic diabetes (PDPD also known as the Jamaica or J-type) [4] the Ethiopian cases were closer to the latter type. However, in contrast to the Jamaican and Indian patients who required 80 IU or more of insulin (at least initially) [5, 6] most of our patients responded to modest doses (50 IU or less) from the start of treatment.
The objectives of this study were to relate the clinical and hormonal (C-peptide and glucagon) responses to glu-cose to the liability of Ethiopian MRDM patients to ketoacidosis during a period of nutritional rehabilitation. These patients would then be compared with Type i (insulin-dependent) and Type2 (non-insulin-dependent) diabetic patients. An additional objective was to re-examine the possibility of treating malnutrition-related diabetic patients with oral agents after nutritional rehabilitation and some recovery of their endogenous insulin secretion.
Patients and methods
The study was conducted at the Ethiopian Nutrition Institute in Addis Ababa over a period of 22 months from June 1986. The purpose of the study was explained and agreement was obtained from each patient and normal control subject (and parents or guardians in the case of minors; minors were not included in the normal control group) participating in the study including their freedom to withdraw from the study at any stage without jeopardy to their care if they did so, in accordance with the Helsinki Declaration. Patients in each category of diabetes (see below) were included in the order in which they were seen (by J.A. and B.M.). Application of various tests, some of which were introduced during the study, was determined by their availability. All information was recorded on a protocol prepared for the purpose. In the case of the MRDM patients, the first objective of treatment was to improve their nutritional status over a period of six to eight weeks. (2) Rapid development of ketoacidosis after insulin withdrawal or in the face of acute stress such as infection, trauma or surgery.
Classification of patients and management
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Management during the study All MRDM patients, and uncontrolled and new Type i patients were admitted to the metabolic ward of the Ethiopian Nutrition Institute for treatment. Their diet contained 1t3 to 120 g of protein allowing at least 1 g/kg body weight of animal protein, 96 to 116 g of fat and total energy 10,000-12,600 kJ (2,700-3,000 kcal) per day. Well-controlled Type 1 and all Type 2 diabetic patients came from their homes on the morning of the test.
Insulin treatment was initiated for MRDM patients on admission to the study. After improvement in their nutritional state (three to four weeks after admission) insulin was withdrawn for trial with glibenclamide (Daonil, Hoechst, Frankfurt, FRG). Insulin was restarted if ketoacidosis or persistent ketonuria (+ + or more on repeated testing with ketostix (Ames (Miles Ltd.), Slough, England)) occurred, or if there were recurrence and progression of the classic symptoms of diabetes despite glibenclamide treatment.
Biochemical procedures and methods
OGTF was performed within two to three weeks of admission according to the standard procedure (75 g glucose in 300 ml of water after withholding insulin from 18.00 hours the day before the test) after relief of the acute symptoms with insulin treatment. Venous blood was sampled every 30 rain through an indwelling needle kept patent with heparinized 154 mmol/1NaCt. Aprotinin (Midran, Novo Industri S/C, Copenhagen, Denmark) was added to the samples for glucagon determination and all the specimens were stored at -20 ~ pending hormone assay.
C-peptide and glucagon were measured by RIA in duplicate samples using reagents supplied by Novo Industri following their directions.
Stool was collected for fat determination (after appropriate treatment in those harbouring intestinal parasites), early in the study for 24 h and later for 72 h at the time of admission and repeated once or twice after nutritional improvement [7] . Norm al controlsubjects (free of intestinal parasites) were put on the same diet as the patients for six days and stoolwas collected for fat determination from day 4 to day 6. D-xylose absorption was determined using the same method [8] as in our previous study. Blood was sampled at 30 min and 60 rain for serum xylose determination (normal values being > 150 mg/1 at 30 min and > 250 mg/1 at 60 min). Unclassified. Patients put in this category were those requiring insulin but without ketosis-proneness or malnutrition in their history or clinical findings and, provisionally, MRDM type patients with age of onset of diabetes above 40 years because they are not included in most MRDM studies.
Statistical methods
Type 2 diabetes. (1)
Patients with hype~ension or kidney disease, or those who were breast feeding were excluded. The Student's t test was used for statistical analysis.
Results
Of a total of 63 patients, 56 males and seven females, included in the category of MRDM initially, two patients were later put in the unclassified category because their history indicated an adequate nutritional background and six others because of onset of symptoms after the age of 40 years. These patients were excluded from the hormonal studies. The age pattern is shown in Table 1 .
Normal control subjects'. The subjects chosen were adults, unrelated to the patients, with a BMI of 19-25 kg/m 2 with normal fasting blood glucose and with no family history of diabetes.
There were 55 MRDM patients, 19 with Type 1 diabetes, 18 with Type 2 diabetes and 16 normal control subjects in various components of the study.
Clinical and biochemical findings
As shown in Table 2 , MRDM patients had many of the physical characteristics associated with malnutrition which were not seen in Type i patients although a BMI of (44) 7 + 2 Haemoglobin (49) < 120 g/1 11 + 2 ( ) = total number tested when less than 55. Numbers after pIus sign apply to the 6 patients aged 40 years and above. a Unrecorded in 5 cases; all other cases normal or above the given value as applicable tients over 40 years old) unselected MRDM patients 14 of them without intestinal parasites. This abnormality was found in only two of 10 Type 1 patients and one of nine control subjects tested. D-xylose absorption was normal in all 12 MRDM patients with excess faecal fat who were tested. Two previously well-nourished but subsequently cachectic Type 2 patients also showed fat malabsorption.
C-peptide and glucagon patterns during OGTT (Tables 4 a and b)
The mean C-peptide values of MRDM patients were higher than those of Type i patients, although the difference was not significant; they were, however, significantly lower than those in Type 2 patients and normal control subjects (p < 0.01 to 0.001 at various times during OGTT in each case). The values were highest in the mild MRDM cases (who responded to the oral agent) approximating those of Type 2 diabetic patients, lowest in the severe group (those who showed ketosis-proneness) being indistinguishable from Type I diabetic patients, and intermediate in the intermediate group (those who required insulin but were ketosis-resistant on insulin interruption). The glucagon secretion patterns were similar in MRDM and Type i diabetes. The values for the ratio of Cpeptide to glucose concentration showed a reversal of the relation of C-peptide levels between Type 2 and normal control subjects. 
Response to treatment
Weight gain in MRDM patients was from 1.1 to 5.4 kg/m 2 on insulin and diet in those who stayed at the Ethiopian Nutrition Institute for four weeks or more except in three patients whose desire for food was reduced by painful neuropathy. The clinical manifestations of malnutrition resolved including reduction in size or disappearance of the parotid enlargement. In three patients who had soft offensive stools the physical characteristics of the stool returned to normal and the fat content also diminished. Abnormal liver function also resolved or improved and there was improvement in haemoglobin levels. < 18 kg/m 2 was also found in some of these patients. Most of the MRDM patients described significant weight loss occurring after the onset of diabetic symptoms. The mean initial BMI of 24 new MRDM patients was 15.60 + 1.45 kg/m 2. There were no MRDM patients with clinical evidence of liver disease at the time of admission to the study but 17 of 47 patients had mild elevation of transaminases, seven (aged 18 years and above) had isolated elevation of alkaline phosphatase and two patients showed elevation of both. Of 10 Type 1 patients tested none showed these abnormalities. Haemoglobin was 120 g/1 or less in 12 of 49 MRDM patients. Fat malabsorption (Table 3) was found in 23 of 39 (plus three pa-
Trial on oral agent (Table 5)
The mean BMI of 24 MRDM patients at the start of oral agent therapy was 18.67 + 1.55 kg/m 2 vs 15.6 + 1.45 kg/m 2 at the time of admission (p < 0.001). The mean duration of the trial was 8.9 days. Only three patients responded and only one had an initial BMI of < 18 kg/m 2. Manifestations of ketoacidosis appeared in two patients and persistent moderate ketonuria in one other within two to four days of starting the oral agent. Another three developed ketonuria without progression to ketoacidosis from day six of treatment while 17 did not show any evidence of ketosis for the duration of their trial as shown in Table 5 but had fasting blood glucose values persistently ' Includes ketoacidosis and persistent ketonuria of + + or more; b 1patient withdrew from the trial after the 3rd day > 11.1 mmol/1, recurrence of polyuria and polydipsia and decline of body weight. The mean age of onset of diabetes of the six patients who developed ketoacidosis or persistent ketonuria during the trial with glibenclamide was 19.7 years, BMI at the time of the trial was 19.2 kg/m 2 (increase in BMI 1.0-5.4 kg/m 2) while the mean age of onset of the 17 who remained ketosis-free during the trial was 23.0 years, the mean BMI was 18.5 kg/m 2 (increase in BMI 1.0~4.8 kg/ma). There was no significant difference between patients in either age of onset of diabetes (t = 1.052, p > 0.3) or BMI at the time of the trial with oral agent (t = 0.914, p > 0.3). In 17 recorded episodes of frank ketoacidosis in 16 Type 1 patients who interrupted their insulin treatment for a variety of reasons, the median interval between interruption of injections and appearance of ketoacidosis was three days and the mean was 5.5 days, the difference between median and mean being due to one patient in whom the interval was recorded as 30 days.
Discussion
We have no ready explanation for the great preponderance of male subjects with MRDM seen in our present and previous studies although other studies have also shown a preponderance of male patients [9] . Most of the MRDM patients were from rural areas and this may mean that debilitated female patients are more reluctant to undertake the long journey to hospital or there may be a true preponderance of males with this type of diabetes. In agreement with our earlier findings [1] , the diabetic patients from a poor socioeconomic environment not only had a low BMI but the other well-known indicators of malnutrition such as parotid enlargement, hair and skin changes, pitting oedema, anaemia (aggravated in some cases by parasitic infestation) and also abnormal liver function tests. These findings are similar to those described by Zuidema from Indonesia [10] with the difference being that among his cases a significant number had pancreatic calcification while, so far, this feature is lacking in Ethiopian MRDM. In our patients the abnormalities improved or resolved during treatment but the severity of the diabetes did not improve in the majority with respect to insulin need for diabetic control. Excess stool fat, not attributable to intestinal parasites, was found in 14 of 39 MRDM patients. This confirms our previous finding of malabsorption in association with MRDM [1] . D-xylose absorption was normal in all 21 patients who had the test. This does not by itself rule out intestinal abnormality but favours pancreatic pathology in conjunction with the postmortem findings in two previous MRDM cases both showing marked reduction in pancreatic size with fibrosis and in one case with areas of polymorphnuclear, lymphocytic and plasma cell infiltration in the acini and islet tissues.
However, exocrine pancreatic pathology (though not pancreatic calcification) also occurs in the Type i and Type 2 diabetes [11] [12] [13] . On the other hand, matabsorption was more common in the MRDM than in Type 1 diabetic patients in this study suggesting an interaction between malnutrition, which is common in Ethiopia [2, 3] and the diabetes in causing the pancreatic damage and producing a condition which, in its most severe form, is akin to kwashiorkor. This hypothesis is strengthened because regression of the parotid enlargement and reduction of the stool fat in some of the patients during treatment suggest that the pancreatic abnormality is partially reversible.
On the other hand, ketoacidosis is not restricted to Type 1 diabetes since it can occur in diabetes developing after near-total pancreatectomy [14] and in the FCPD variant of MRDM [15] . Therefore, based on clinical characteristics alone, even ketoacidosis cannot provide conclusive evidence of the aetiological category of the diabetes [16] .
Concerning ketosis-resistance in MRDM, this study has confirmed our earlier findings and those of others [1, 2, 15] that the majority of patients exhibit this characteristic on insulin withdrawal in comparison to Type 1 diabetic patients, even after a significant gain in body weight, for a longer period than the average Type i patient although our patients were not withdrawn from insulin for as long as those in the study by Ahuja et al. [17] . Furthermore, the serum carnitine level of Ethiopian diabetic patients was not found to be significantly lower than that of normal control subjects although the nutritional state of the patients tested is not obvious in the report [18] .
Weight gain during nutritional rehabilitation in the six MRDM patients who developed ketoacidosis or significant ketonuria and the 17 who did not was similar and glucagon secretion patterns in MRDM and Type 1 diabetes were also similar. On the other hand, the C-peptide in the MRDM group was consistently (though not significantly) higher than that in the Type 1 group. Furthermore, in the MRDM group it was highest in the oral agent responsive group and lowest in the ketosis-prone group. These findings are in favour of residual insulin secretion as the main factor for ketosis-resistance in MRDM. But aggravation of carnitine and body fat depletion in the course of the diabetes could be contributory factors. However, levels indistinguishable from those with Type 1 diabetes as well as wide variations in basal and stimulated levels similar to those found in this study have been reported in MRDM [19, 20] . These differences may be partly due to differences in the nutritional and metabolic status of the patients when the test is done. In addition, the possibility, also applying to our study, that ketosis-prone patients from rural areas are less likely to reach medical care because of rapid progression to ketoacidosis, thus contributing an inherent bias in the clinical identification of MRDM.
The geography of diabetes [21, 22] shows that MRDM is confined to tropical countries where malnutrition is common and in most of these countries it is peculiar to the poorer segment of the population but such an association does not necessarily indicate a cause-effect relationship. Therefore, the aetiology of MRDM remains unresolved [23] .
On the basis of several characteristics including onset in youth, insulin treatment required and ketosis-proneness, developing in some cases during the natural history or after nutritional rehabilitation and the glucagon and Cpeptide levels, the PDPD variant of MRDM could be considered a mild form or variant of Type 1 diabetes peculiar to malnourished populations rather than an aetiologically separate entity. In addition, a limited study of the HLA pattern in MRDM patients has shown a significantly higher frequency of HLA-DR3 than in non-diabetic control subjects and similar to that in Type 1 diabetes in the same population [24] . However, a definitive answer to its identity requires more extensive community-based studies to ascertain frequency and type of diabetes in malnourished populations and the role of genetics and environment in their aetiology.
